To determine whether dipyridamole or aspirin + dipyridamole would produce significant reduction in the subsequent occurrence of reversible ischemic attacks and completed stroke.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Non-randomized clinical trial of 244 patients.
Patients with a known history of peptic ulcer, active ulcer, hiatal hernia, intolerance to ASA or non-specific dyspepsia were assigned to receive dipyridamole alone (400 mg/day in two 50 mg capsules given 4 times daily). All other patients were assigned to receive dipyridamole (300 mg/day in two 50 mg capsules given 3 times daily) and ASA (100 mg/48 h). Patients received follow-up visits every 3 months for an average of 21 months. Patients were withdrawn if they were lost to follow-up, failed to take the study medication for 1 month, started taking other platelet aggregation inhibiting drugs, underwent surgery, or suffered mitral valve prolapse or paroxysmal atrial fibrillation.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Complete stroke, death, transient ischemic attack (TIA), reversible ischemic neurologic deficit (RIND), reversible ischemic neurologic deficit with incomplete resolution (RIND-IR).|